[Analysis of the factors influencing the severity of coronavirus disease 2019 in patients with myeloproliferative neoplasms based on an online questionnaire].

F Y Qi, M Bao, H L Gao, Q Jiang
{"title":"[Analysis of the factors influencing the severity of coronavirus disease 2019 in patients with myeloproliferative neoplasms based on an online questionnaire].","authors":"F Y Qi, M Bao, H L Gao, Q Jiang","doi":"10.3760/cma.j.cn112138-20230822-00073","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective:</b> To explore the variables associated with the severity of coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2 omicron variant during the epidemic in patients with myeloproliferative neoplasms (MPN). <b>Methods:</b> A cross-sectional study. During the SARS-CoV-2 omicron variant pandemic from December 15, 2022, to March 15, 2023, COVID-19 related data for patients with MPN who were treated at Peking University People's Hospital were collected through an online questionnaire-based survey. All questionnaires and clinical data were checked by medical assistants. Logistic multivariate analysis was used to explore the prevalence and variables associated with the severity of COVID-19 in patients with MPN. <b>Results:</b> A total of 239 patients with MPN, including 90 (37.7%) presenting with essential thrombocythemia (ET), 50 (20.9%) with polycythemia vera (PV), and 99 (41.4%) with myelofibrosis (MF), were enrolled in the study. The 99 patients with MF included 87 (87.9%) with primary MF, 5 (5.1%) with post-PV MF, and 7 (7.1%) with post-ET MF. Overall, 239 (100%) patients reported that they experienced COVID-19 during the pandemic. Of these, 226 (94.6%) had mild disease, 4 (1.7%) had moderate disease, 7 (2.9%) had severe disease, and 2 (0.8%) had critical disease. Two (0.8%) patients with severe COVID-19 died, one of which suffered from MT and the other from PV. Multivariate analysis showed that older age (<i>OR</i>=2.36, 95%<i>CI</i> 1.24-4.49), MF (<i>OR</i>=10.22, 95%<i>CI</i> 1.13-92.80), or comorbidity (<i>OR</i>=5.25, 95%<i>CI</i> 1.25-22.03) were associated with a significantly higher risk of developing moderate, severe, or critical COVID-19. Among patients with MF, higher risk stratification reflected an increased risk of developing moderate, severe, or critical COVID-19 (<i>P</i>=0.034). <b>Conclusion:</b> During the omicron pandemic, older age, MF (especially higher-risk categories), and comorbidity were associated with a higher risk of developing moderate, severe, or critical COVID-19.</p>","PeriodicalId":68309,"journal":{"name":"中华内科杂志","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华内科杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.cn112138-20230822-00073","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To explore the variables associated with the severity of coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2 omicron variant during the epidemic in patients with myeloproliferative neoplasms (MPN). Methods: A cross-sectional study. During the SARS-CoV-2 omicron variant pandemic from December 15, 2022, to March 15, 2023, COVID-19 related data for patients with MPN who were treated at Peking University People's Hospital were collected through an online questionnaire-based survey. All questionnaires and clinical data were checked by medical assistants. Logistic multivariate analysis was used to explore the prevalence and variables associated with the severity of COVID-19 in patients with MPN. Results: A total of 239 patients with MPN, including 90 (37.7%) presenting with essential thrombocythemia (ET), 50 (20.9%) with polycythemia vera (PV), and 99 (41.4%) with myelofibrosis (MF), were enrolled in the study. The 99 patients with MF included 87 (87.9%) with primary MF, 5 (5.1%) with post-PV MF, and 7 (7.1%) with post-ET MF. Overall, 239 (100%) patients reported that they experienced COVID-19 during the pandemic. Of these, 226 (94.6%) had mild disease, 4 (1.7%) had moderate disease, 7 (2.9%) had severe disease, and 2 (0.8%) had critical disease. Two (0.8%) patients with severe COVID-19 died, one of which suffered from MT and the other from PV. Multivariate analysis showed that older age (OR=2.36, 95%CI 1.24-4.49), MF (OR=10.22, 95%CI 1.13-92.80), or comorbidity (OR=5.25, 95%CI 1.25-22.03) were associated with a significantly higher risk of developing moderate, severe, or critical COVID-19. Among patients with MF, higher risk stratification reflected an increased risk of developing moderate, severe, or critical COVID-19 (P=0.034). Conclusion: During the omicron pandemic, older age, MF (especially higher-risk categories), and comorbidity were associated with a higher risk of developing moderate, severe, or critical COVID-19.

[基于在线问卷对骨髓增生性肿瘤患者 2019 年冠状病毒疾病严重程度的影响因素分析]。
目的探讨骨髓增生性肿瘤(MPN)患者在流行期间由 SARS-CoV-2 omicron 变体引起的冠状病毒病 2019(COVID-19)严重程度的相关变量。方法:横断面研究:横断面研究。在 2022 年 12 月 15 日至 2023 年 3 月 15 日 SARS-CoV-2 omicron 变体大流行期间,通过在线问卷调查收集了在北京大学人民医院接受治疗的骨髓增殖性肿瘤患者的 COVID-19 相关数据。所有问卷和临床数据均由医疗助理进行核对。采用逻辑多变量分析法探讨 MPN 患者 COVID-19 的患病率以及与 COVID-19 严重程度相关的变量。结果共有239名骨髓增生性疾病患者参与了研究,其中包括90名(37.7%)原发性血小板增多症(ET)患者、50名(20.9%)真性多血细胞增多症(PV)患者和99名(41.4%)骨髓纤维化(MF)患者。在 99 名骨髓纤维化患者中,87 人(87.9%)为原发性骨髓纤维化,5 人(5.1%)为 PV 后骨髓纤维化,7 人(7.1%)为ET 后骨髓纤维化。总体而言,239 名(100%)患者报告在大流行期间经历过 COVID-19。其中,226 人(94.6%)病情轻微,4 人(1.7%)病情中度,7 人(2.9%)病情严重,2 人(0.8%)病情危重。两名(0.8%)重度 COVID-19 患者死亡,其中一名患有 MT,另一名患有 PV。多变量分析显示,年龄较大(OR=2.36,95%CI 1.24-4.49)、MF(OR=10.22,95%CI 1.13-92.80)或合并症(OR=5.25,95%CI 1.25-22.03)与罹患中度、重度或危重COVID-19的风险显著升高有关。在中耳炎患者中,风险分层越高,患中度、重度或危重 COVID-19 的风险越高(P=0.034)。结论在奥米克大流行期间,高龄、MF(尤其是高风险类别)和合并症与罹患中度、重度或危重 COVID-19 的较高风险有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.00
自引率
0.00%
发文量
19688
期刊介绍:
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信